Modified protocols for surfactant therapy in experimental meconium aspiration syndrome

被引:19
|
作者
Tashiro, K
Cui, XG
Kobayashi, T
Curstedt, T
Robertson, B
机构
[1] Karolinska Hosp, Lab Surfactant Res, SE-17176 Stockholm, Sweden
[2] Karolinska Hosp, Sect Clin Chem, Dept Surg Sci, SE-17176 Stockholm, Sweden
[3] Kanazawa Univ, Grad Sch Med, Dept Anesthesia & Intens Care Med, Kanazawa, Ishikawa 920, Japan
来源
BIOLOGY OF THE NEONATE | 2003年 / 83卷 / 01期
关键词
dextran; meconium aspiration syndrome; rats; pulmonary surfactant; surface tension;
D O I
10.1159/000067009
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
In adult rats with experimental meconium aspiration syndrome, we investigated whether the therapeutic effect of exogenous surfactant was increased by addition of dextran or preceding airway lavage with diluted surfactant. Animals (n = 72) ventilated with pure oxygen were given human meconium suspension (50-75 mg kg(-1)) through the airways. When the PaO2 had decreased to <20 kPa (mean +/- SD 12 +/- 3.9 kPa), the rats were randomly allocated to ten groups (G). G 6-10 underwent lung lavage with diluted Curosurf (5 mg ml(-1), 20 ml kg(-1)), whereas G 1-5 did not. G 1 and 6 received no additional material through the airways. G 2 and 7 received Curosurf (100 mg kg(-1)), and G 3 and 8 received Curosurf (100 mg kg(-1)) plus dextran (75 mg kg-1); G 4 and 9 received Curosurf (200 mg kg(-1)), and G 5 and G 10 received Curosurf (200 mg kg(-1)) plus dextran (75 mg kg(-1)). All rats in G 1 died before 180 min after randomization. In G 2, 3, 6, 7, and 8, the PaO2 transiently increased to 30-40 kPa. In G 4, 5, 9, and 10, the PaO2 remained >30 kPa for 180 min. Both airway lavage and supplementation with dextran improved the therapeutic effects of surfactant; however, a large dose (200 mg kg(-1)) was nevertheless required to optimize gas exchange. Copyright (C) 2003 S. Karger AG, Basel.
引用
收藏
页码:49 / 56
页数:8
相关论文
共 50 条
  • [1] SURFACTANT REPLACEMENT THERAPY FOR MECONIUM ASPIRATION SYNDROME
    FINDLAY, RD
    TAEUSCH, HW
    WALTHER, FJ
    PEDIATRIC RESEARCH, 1994, 35 (04) : A332 - A332
  • [2] Surfactant replacement therapy for meconium aspiration syndrome
    Findlay, RD
    Taeusch, HW
    Walther, FJ
    PEDIATRICS, 1996, 97 (01) : 48 - 52
  • [3] Meconium-induced oxidative damage and surfactant/budesonide therapy in experimental meconium aspiration syndrome
    Mikolka, Pavol
    Kopincova, J.
    Mokra, D.
    Tomcikova, L.
    Calkovska, A.
    ACTA PHYSIOLOGICA, 2014, 211 : 108 - 109
  • [4] N-acetylcysteine potentiates surfactant therapy for experimental meconium aspiration syndrome
    Kopincova, Jana
    Mikolka, Pavol
    Mokra, Daniela
    Calkovska, Andrea
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [5] Surfactant therapy for meconium aspiration syndrome - Current status
    Dargaville, PA
    Mills, JF
    DRUGS, 2005, 65 (18) : 2569 - 2591
  • [6] The burden of illness for meconium aspiration syndrome and cost prediction related to surfactant therapy for meconium aspiration syndrome in Korea
    Choi, Hyun Jin
    Suh, Hae Sun
    Hahn, Seokyung
    Lee, Joongyub
    Park, Byung-Joo
    Lee, Soon Min
    Kim, Han-Suk
    Bae, Chong-Woo
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2011, 54 (05): : 549 - 556
  • [7] Surfactant and surfactant inhibitors in meconium aspiration syndrome
    Dargaville, PA
    South, M
    McDougall, PN
    JOURNAL OF PEDIATRICS, 2001, 138 (01): : 113 - 115
  • [8] The influence of surfactant therapy on the radiographic appearance of meconium aspiration syndrome
    Fefferman, NR
    Roche, KJ
    Ambrosino, MM
    Genieser, NB
    RADIOLOGY, 1997, 205 : 1381 - 1381
  • [9] Modified porcine surfactant enriched by recombinant human superoxide dismutase for experimental meconium aspiration syndrome
    Kopincova, Jana
    Mikolka, Pavol
    Kolomaznik, Maros
    Kosutova, Petra
    Calkovska, Andrea
    Mokra, Daniela
    LIFE SCIENCES, 2018, 203 : 121 - 128